Buprenorphine Injection

Introduction Overview

Generic Name

buprenorphine injection

Brand Name

Buprenex

Dosage Form

Injection (intramuscular or intravenous)

Drug Class

Opioids (narcotic analgesics)

Pharmacokinetics

Absorption

Buprenex is administered parenterally via intramuscular (IM) or slow intravenous (IV) injection, ensuring rapid and complete absorption into systemic circulation. When given IM, onset of analgesic effect is typically within 15 minutes, with peak effects occurring around 1 hour post-injection, and analgesia lasting up to 6 hours or longer. IV administration results in an even faster onset of pain relief with a shorter peak effect duration. The bioavailability following parenteral administration is essentially 100% due to direct entry into systemic circulation, bypassing first-pass metabolism.

Distribution

Buprenorphine exhibits extensive distribution throughout the body, characterized by a large volume of distribution, approximating 64 L/kg, indicating extensive tissue binding. It is highly lipophilic, facilitating penetration into the central nervous system where it exerts its analgesic effects. Buprenorphine is substantially bound to plasma proteins (~96%), primarily albumin. Due to high lipid solubility, it rapidly crosses the blood-brain barrier, achieving effective concentrations at opioid receptors in the brain and spinal cord.

Metabolism

Buprenorphine undergoes extensive hepatic metabolism primarily via the cytochrome P450 3A4 (CYP3A4) enzyme. The major metabolic pathway is N-dealkylation producing the active metabolite norbuprenorphine, which possesses opioid activity but does not readily cross the blood-brain barrier. Buprenorphine and its metabolites also undergo conjugation by glucuronidation. The metabolism is subject to interindividual variability due to CYP3A4 induction or inhibition by concomitant drugs, affecting plasma concentrations and clinical effects.

Elimination

Elimination of buprenorphine is primarily via biliary excretion into the feces, with less than 10% excreted renally as unchanged drug or metabolites. The terminal elimination half-life ranges from 20 to 70 hours depending on the route and formulation. Its prolonged half-life contributes to sustained analgesic effects and influences dosing intervals. Enterohepatic recirculation may occur, influencing plasma levels. Clearance may be reduced in hepatic impairment, necessitating careful monitoring.

Dosage Forms

Adults

Buprenex injection is available as an injectable solution for intramuscular or intravenous use. The usual adult dosage for pain management is an initial dose of 0.3 mg given deep IM or slow IV over at least 2 minutes. This dose may be repeated once after 30 to 60 minutes if necessary. Subsequently, 0.3 mg IV/IM may be administered every 6 hours as needed. Maximum single doses are 0.3 mg IV or 0.6 mg IM for patients not at high risk. Dosing should employ the lowest effective dose for the shortest duration, tailored to pain severity and patient response.

Adolescents

In pediatric patients aged 2 to 12 years, the recommended dose is 2 to 6 mcg/kg administered IM or slow IV every 4 to 6 hours as needed. Some pediatric patients may require longer inter-dose intervals (6 to 8 hours) and fixed interval dosing is generally avoided until an appropriate dosing interval is established. For adolescents over 12 years, adult dosing applies (0.3 mg IM/IV every 6 hours as needed). Close monitoring for sedation and respiratory depression is critical.

Special Populations

Use in patients with hepatic or renal impairment should be cautious, with possible dose adjustments and careful monitoring due to altered metabolism and elimination. Elderly patients and those debilitated or with chronic pulmonary disease are at increased risk of respiratory depression and require careful titration and vigilant supervision. Buprenex should be avoided or used with extreme caution in patients with severe asthma or significant respiratory compromise. Pregnancy use is associated with risk of neonatal opioid withdrawal; benefits versus risks should be carefully assessed. Breastfeeding is contraindicated due to risk of serious adverse reactions in nursing infants.

Mechanism Of Action

Buprenorphine, the active ingredient in Buprenex, is a potent partial agonist at the mu-opioid receptor (MOR) with high affinity and slow dissociation, producing analgesia by modulating pain pathways in the central nervous system. Unlike full opioid agonists such as morphine or oxycodone, buprenorphine elicits a ceiling effect at high receptor occupancy, resulting in a reduced risk of respiratory depression and dependence. This partial agonist activity contributes to analgesia while limiting some typical opioid side effects.

In addition to mu-opioid receptor partial agonism, buprenorphine acts as an antagonist at the kappa-opioid receptor subtype, which may contribute to its unique clinical effects, including diminished dysphoria and potentially reduced development of tolerance. Buprenorphine also exhibits weak agonist activity at the opioid receptor-like 1 (ORL1) receptor, which may influence analgesic tone and modulate opioid-related side effects.

Buprenorphine produces analgesia by inhibiting ascending pain signals as well as altering perception and emotional response to pain through receptor activation in the brain and spinal cord. Its high receptor affinity allows it to displace other opioids from receptors, which has implications for its use in opioid dependency treatment and potential interactions with other opioids.

Clinical studies demonstrate that buprenorphine’s unique receptor binding and partial agonist profile result in effective pain control with a lower risk of respiratory depression, making Buprenex suitable for moderate to severe pain management, especially when other analgesics are inadequate or contraindicated.

Pharmacological Actions

Partial agonist activity at mu-opioid receptors producing analgesia
Antagonist action at kappa-opioid receptors potentially reducing dysphoria
High receptor affinity with slow dissociation increasing duration of effect
Modulation of pain pathways in the central nervous system, including spinal and supraspinal sites
Ceiling effect limiting respiratory depression risk compared to full opioid agonists
Produces sedation and anxiolysis via central opioid receptor interaction
Suppresses transmission of nociceptive signals from peripheral nerves to brain
Causes pupillary constriction (miosis) through parasympathetic nervous system activation
Reduces gastrointestinal motility leading to constipation
Induces endocrine changes such as hormone release modulation

Therapeutic Clinical Uses

Management of moderate to severe acute pain requiring opioid analgesia
Postoperative pain control when non-opioid analgesics are insufficient
Pain management in patients unable to take oral medications
Treatment of pain in pediatric patients aged 2 years and older
Adjunctive analgesic in chronic pain conditions under specialist supervision
Use in patients with diminished renal function due to minimal renal excretion
Component of pain management protocol in hospital settings requiring injectable opioid
Managing breakthrough pain in opioid-tolerant patients (off-label)

Side Or Adverse Effects

Respiratory depression, especially with rapid IV administration or overdose
Drowsiness and sedation potentially impairing alertness
Nausea and vomiting frequently reported
Dizziness and vertigo due to central nervous system effects
Pinpoint pupils (miosis) as a characteristic opioid effect
Increased sweating and flushing
Constipation from reduced gastrointestinal motility
Headache
Rare allergic reactions including rash and anaphylaxis
Potential for serotonin syndrome when used with serotonergic drugs
Risk of dependence and withdrawal symptoms upon abrupt discontinuation
Injection site irritation and potential local reactions

Precautions

Use caution in patients with respiratory disorders such as COPD or sleep apnea
Avoid use in severe asthma or acute bronchial asthma episodes
Monitor closely in patients with head injury or increased intracranial pressure
Adjust dosing carefully in patients with liver or kidney impairment
Avoid concurrent use with other CNS depressants without close supervision
Monitor for signs of serotonin syndrome with concomitant serotonergic medications
Avoid in patients with bowel obstruction or paralytic ileus
Use lowest effective dose for shortest duration to minimize abuse risk
Avoid use in patients with history of substance abuse unless carefully monitored
Monitor elderly and debilitated patients for increased sensitivity and respiratory depression

Warnings

Potential for addiction, abuse, and misuse which may lead to overdose or death
Using Buprenex in pregnancy may result in neonatal opioid withdrawal syndrome requiring medical intervention
Fatal respiratory depression can occur, especially with concomitant alcohol or CNS depressants
Monitor vital signs, especially respiratory rate and oxygenation during therapy
Never share medication; keep securely to prevent misuse
Use extreme caution with IV administration due to rapid onset and risk of apnea
Delayed or prolonged respiratory depression has been reported
Drug interactions can increase risk of life-threatening side effects
Avoid breastfeeding during treatment due to potential for serious adverse reactions in infant
Careful monitoring for opioid withdrawal symptoms if discontinuing treatment

Contraindications

Known hypersensitivity or allergy to buprenorphine or formulation components
Severe respiratory depression or acute respiratory distress
Acute or severe bronchial asthma or hypercarbia
Gastrointestinal obstruction including paralytic ileus
Patients with significant head injury, increased intracranial pressure or coma
Use in patients with known or suspected bowel obstruction
Concomitant use with medications contraindicated due to interactions
Use in opioid-naïve patients requiring high-dose opioid therapy without modification
Patients with severe hepatic impairment without close monitoring
Patients who have experienced opioid-induced anaphylactic reactions

Drug Interactions

Enhanced central nervous system depression with alcohol, benzodiazepines, sedatives, muscle relaxants, and other opioids
Increased risk of respiratory depression when combined with other CNS depressants
Potential serotonin syndrome with concomitant serotonergic agents (e.g., SSRIs, SNRIs, triptans)
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase buprenorphine levels leading to toxicity
CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce buprenorphine efficacy
Additive hypotensive effects with antihypertensives
Interaction with stimulant medications potentially altering therapeutic response
Use caution with medications prolonging QT interval due to arrhythmia risk
Herbal products like St. John's Wort may reduce effectiveness through CYP induction
Interactions with drugs used for migraine, depression, Parkinson's disease warrant monitoring

Preparations Of The Drug

Buprenex Injection: sterile injectable solution for intramuscular or intravenous use
Supplied in multiple vial sizes according to hospital pharmacy standards
Formulated for slow IV push or deep IM injection
No oral or sublingual forms under the Buprenex brand; other buprenorphine brands available in different formulations
Packaging includes instructions for safe handling and administration by healthcare professionals